Biogen expands ophthalmology portfolio with $310m biosimilar deal 07-Nov-2019 By Ben Hargreaves Biogen strikes deal with Samsung Bioepis for the commercial rights to two biosimilars referencing Lucentis and Eylea.
Genentech looks to market first eye implant for AMD 03-Aug-2018 By Ben Hargreaves Genentech has developed an implant to deliver ranibizumab directly into the eye of patients.
